How effective is Ramucirumab?

In many major studies, Ramucirumab has been found to be effective in patients with advanced gastric or gastroesophageal junction cancer, metastatic colorectal cancer, advanced or metastatic non-small cell lung cancer, and hepatocellular carcinoma, with benefits outweighing risks.

In a major study involving665 patients with advanced gastric or gastroesophageal junction cancer whose disease worsened despite treatment with platinum- and fluoropyrimidine-containing drugs who received ramucizumab< The average survival time of patients treated with paclitaxel and paclitaxel was 9.6 months. In another study of 355 patients, patients who received ramucirumab plus best supportive care lived longer, an average of 5.2 months. In a major study of 1,072 patients with metastatic colorectal cancer whose disease worsened despite treatment with bevacizumab, oxaliplatin, and fluoropyrimidine, patients treated with ramucirumab and FOLFIRI lived an average of 13.3 months.

In a major study involving449 patients with metastatic non-small cell lung cancer and EGFR mutations, patients who receivedramucizumab and erlotiniblived an average of 19 months without their cancer getting worse. In another major study involving 1,253 patients with advanced or metastatic non-small cell lung cancer whose disease worsened despite treatment with platinum-containing drugs, those who received ramucirumab and docetaxel lived an average of 10.5 months. In a study involving 292 patients with advanced or unresectable hepatocellular carcinoma who had high AFP blood levels and had been previously treated with sorafenib, patients who received ramucirumab survived on average 8.5 months.